DK0979090T3 - Aminosukker, glycosaminoglycan eller glycosaminoglycan-lignende forbindelser og S-adenosylmethionin - Google Patents

Aminosukker, glycosaminoglycan eller glycosaminoglycan-lignende forbindelser og S-adenosylmethionin

Info

Publication number: DK0979090T3
Authority: DK; Denmark
Prior art keywords: composition; glycosaminoglycan; salts; sulfate; connective tissue
Prior art date: 1997-04-28

Application number

DK98915591T

Other languages

Danish (da)

English (en)

Inventor

Robert W Henderson

Todd Henderson

Tarek Hammad

Original Assignee

Nutramax Lab Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-04-28

Filing date

1998-04-17

Publication date

2009-06-08

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25296238&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0979090(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1998-04-17 Application filed by Nutramax Lab Inc filed Critical Nutramax Lab Inc

2009-06-08 Application granted granted Critical

2009-06-08 Publication of DK0979090T3 publication Critical patent/DK0979090T3/da

Links

229920002683 Glycosaminoglycan Polymers 0.000 title abstract 3
MEFKEPWMEQBLKI-AIRLBKTGSA-N S-adenosyl-L-methioninate Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-N 0.000 title abstract 3
229960001570 ademetionine Drugs 0.000 title abstract 3
150000001875 compounds Chemical class 0.000 title abstract 3
150000002337 glycosamines Chemical class 0.000 title abstract 2
239000000203 mixture Substances 0.000 abstract 7
210000002808 connective tissue Anatomy 0.000 abstract 3
KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 abstract 3
241000124008 Mammalia Species 0.000 abstract 2
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 abstract 2
MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 abstract 2
DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 abstract 2
OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 abstract 2
239000012634 fragment Substances 0.000 abstract 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 2
150000003839 salts Chemical class 0.000 abstract 2
KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 abstract 1
CBOJBBMQJBVCMW-BTVCFUMJSA-N (2r,3r,4s,5r)-2-amino-3,4,5,6-tetrahydroxyhexanal;hydrochloride Chemical compound Cl.O=C[C@H](N)[C@@H](O)[C@H](O)[C@H](O)CO CBOJBBMQJBVCMW-BTVCFUMJSA-N 0.000 abstract 1
RBCOYOYDYNXAFA-UHFFFAOYSA-L (5-hydroxy-4,6-dimethylpyridin-3-yl)methyl phosphate Chemical compound CC1=NC=C(COP([O-])([O-])=O)C(C)=C1O RBCOYOYDYNXAFA-UHFFFAOYSA-L 0.000 abstract 1
MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 abstract 1
MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 abstract 1
REEBJQTUIJTGAL-UHFFFAOYSA-N 3-pyridin-1-ium-1-ylpropane-1-sulfonate Chemical compound [O-]S(=O)(=O)CCC[N+]1=CC=CC=C1 REEBJQTUIJTGAL-UHFFFAOYSA-N 0.000 abstract 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract 1
229920002567 Chondroitin Polymers 0.000 abstract 1
IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 abstract 1
229920002971 Heparan sulfate Polymers 0.000 abstract 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract 1
206010061218 Inflammation Diseases 0.000 abstract 1
229920000288 Keratan sulfate Polymers 0.000 abstract 1
102000011782 Keratins Human genes 0.000 abstract 1
108010076876 Keratins Proteins 0.000 abstract 1
PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 abstract 1
FFDGPVCHZBVARC-UHFFFAOYSA-N N,N-dimethylglycine Chemical compound CN(C)CC(O)=O FFDGPVCHZBVARC-UHFFFAOYSA-N 0.000 abstract 1
OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 abstract 1
OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 abstract 1
OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 abstract 1
MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 abstract 1
239000002253 acid Substances 0.000 abstract 1
229960003237 betaine Drugs 0.000 abstract 1
239000011575 calcium Substances 0.000 abstract 1
229910052791 calcium Inorganic materials 0.000 abstract 1
FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 abstract 1
229940019765 dermatin Drugs 0.000 abstract 1
108700003601 dimethylglycine Proteins 0.000 abstract 1
FEBLZLNTKCEFIT-VSXGLTOVSA-N fluocinolone acetonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O FEBLZLNTKCEFIT-VSXGLTOVSA-N 0.000 abstract 1
229960000304 folic acid Drugs 0.000 abstract 1
235000019152 folic acid Nutrition 0.000 abstract 1
239000011724 folic acid Substances 0.000 abstract 1
229960002442 glucosamine Drugs 0.000 abstract 1
150000002301 glucosamine derivatives Chemical class 0.000 abstract 1
229960001911 glucosamine hydrochloride Drugs 0.000 abstract 1
229920002674 hyaluronan Polymers 0.000 abstract 1
229960003160 hyaluronic acid Drugs 0.000 abstract 1
IAJILQKETJEXLJ-LECHCGJUSA-N iduronic acid Chemical compound O=C[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-LECHCGJUSA-N 0.000 abstract 1
230000004054 inflammatory process Effects 0.000 abstract 1
KXCLCNHUUKTANI-RBIYJLQWSA-N keratan Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@H](COS(O)(=O)=O)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H]([C@@H](COS(O)(=O)=O)O[C@@H](O)[C@@H]3O)O)[C@H](NC(C)=O)[C@H]2O)COS(O)(=O)=O)O[C@H](COS(O)(=O)=O)[C@@H]1O KXCLCNHUUKTANI-RBIYJLQWSA-N 0.000 abstract 1
229910052748 manganese Inorganic materials 0.000 abstract 1
239000011572 manganese Substances 0.000 abstract 1
239000011159 matrix material Substances 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
229950006780 n-acetylglucosamine Drugs 0.000 abstract 1
239000011734 sodium Substances 0.000 abstract 1
229910052708 sodium Inorganic materials 0.000 abstract 1
229940045999 vitamin b 12 Drugs 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/32—Manganese; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Rheumatology (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pain & Pain Management (AREA)
Immunology (AREA)
Inorganic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

DK98915591T 1997-04-28 1998-04-17 Aminosukker, glycosaminoglycan eller glycosaminoglycan-lignende forbindelser og S-adenosylmethionin DK0979090T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US08/845,852 US6255295B1 (en)	1996-12-23	1997-04-28	Aminosugar, glycosaminoglycan or glycosaminoglycan-like compounds, and s-adenosylmethionine composition for the protection, treatment, repair, and reduction of inflammation of connective tissue
PCT/US1998/007561 WO1998048816A1 (en)	1997-04-28	1998-04-17	Aminosugar, glycosaminoglycan or glycosaminoglycan-like compounds, and s-adenosylmethionine

Publications (1)

Publication Number	Publication Date
DK0979090T3 true DK0979090T3 (da)	2009-06-08

Family

ID=25296238

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK98915591T DK0979090T3 (da)	1997-04-28	1998-04-17	Aminosukker, glycosaminoglycan eller glycosaminoglycan-lignende forbindelser og S-adenosylmethionin

Country Status (12)

Country	Link
US (1)	US6255295B1 (de)
EP (2)	EP1849471B1 (de)
AT (2)	ATE489099T1 (de)
AU (1)	AU747595B2 (de)
CA (3)	CA2539696A1 (de)
CY (1)	CY1109064T1 (de)
DE (2)	DE69842021D1 (de)
DK (1)	DK0979090T3 (de)
ES (2)	ES2324565T3 (de)
NZ (1)	NZ500025A (de)
PT (1)	PT979090E (de)
WO (1)	WO1998048816A1 (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20010000472A1 (en) *	1998-02-27	2001-04-26	Nutramax Laboratories, Inc.	L-ergothioneine, milk thistle, and s-adenosylmethionine for the prevention, treatment and repair of liver damage
AU7822798A (en) *	1998-06-04	1999-12-20	Nutramax Laboratories, Inc.	Aminosugar, glycosaminoglycan, and s-adenosylmethionine composition for the treatment and repair of connective tissue
DE69935140T2 (de) *	1998-06-05	2007-05-31	Nutramax Laboratories, Inc.	Verwendung von anabolika, anti-katabolischen mitteln, antioxidanzien und analgetika zum schutz, zur behandlung und reparation von bindegeweben in menschen und tieren
EP1762247A1 (de) *	1998-06-05	2007-03-14	Nutramax Laboratories, Inc.	Verwendung von Anabolika, antikatabolischen Mitteln, Antioxidationsmittel und Analgetika zum Schutz sowie zur Behandlung und Wiederherstellung von Bindegewebe bei Menschen und Tieren
US6656925B2 (en) *	1998-09-09	2003-12-02	Advanced Medical Instruments	Composition and method of treating arthritis
US20020018787A1 (en)	1999-05-21	2002-02-14	Roger V. Kendall	Methods and compositions for modulating immune response and for the treatment of inflammatory disease
DE60038320D1 (de) *	1999-07-21	2008-04-24	Bomac Research Ltd	Mittel zur bekämpfung von entzündungen und/oder degenerativen erkrankungen
US6524609B1 (en) *	1999-08-18	2003-02-25	Nutri-Vet, Llc	Treating arthritis in animals with dietary supplements
WO2001026646A1 (en) *	1999-10-08	2001-04-19	Pharmnseas, Inc.	NUTRACEUTICAL PRODUCTS CONTAINING SAMe AND DIETARY SUPPLEMENTS AND METHOD OF MANUFACTURING AND USE THEREOF
DE20004010U1 (de)	2000-03-02	2000-06-21	Febena Pharma GmbH, 50825 Köln	Diätische Zusammensetzung mit einem Gehalt an Glycosaminoglycanen
US20050282774A1 (en) *	2000-10-31	2005-12-22	Eek Bjorn C	Method and pharmaceutical to treat spinal discs
CA2435637A1 (en)	2001-01-23	2002-08-01	Massachusetts Institute Of Technology	Solid- and solution -phase synthesis of heparin and other glycosaminoglycans
US6916492B2 (en)	2001-03-30	2005-07-12	Council Of Scientific & Industrial Research	Natural nontoxic multicolor fluorescent protein dye from a marine invertebrate, compositions containing the said dye and its uses
US6689391B2 (en)	2001-03-30	2004-02-10	Council Of Scientific & Industrial Research	Natural non-polar fluorescent dye from a non-bioluminescent marine invertebrate, compositions containing the said dye and its uses
BRPI0101486B1 (pt) *	2001-04-17	2017-09-19	Cristália Produtos Químicos Farmacêuticos Ltda.	Pharmaceutical composition for topic use containing heparin for the treatment of skin or mucosal injuries caused by burns
US20030138543A1 (en) *	2002-01-03	2003-07-24	Bradley T. Baumann	Food product supplemented with proteoglycan precursors
US20030134825A1 (en) *	2002-01-03	2003-07-17	Robert Bahoshy	Food product supplemented with proteoglycan precursors
US7387796B2 (en) *	2002-01-30	2008-06-17	Hebert Rolland F	Stable compositions of S-adenosyl-l-methionine with dextran
WO2003068249A1 (en) *	2002-02-15	2003-08-21	Ocean Nutrition Canada Limited	Shark cartilage extracts and use thereof for immunomodulation
US20030170374A1 (en) *	2002-03-05	2003-09-11	Robert Bahoshy	Condiments including nutritional supplements
SI1496917T1 (sl) *	2002-04-19	2006-06-30	Astion Dev As	Kombinacija beta-2-adrenoceptorskih agonistov in aminosladkorjev in njihova uporaba za zdravljenje imonomodulatornih motenj
US7485629B2 (en) *	2002-10-16	2009-02-03	Arthrodynamic Technologies, Animal Health Division, Inc.	Composition and method for treatment of joint damage
US7504387B2 (en) *	2002-10-16	2009-03-17	Arthrodynamic Technologies, Animal Health Division, Inc.	Glycosaminoglycan composition and method for treatment and prevention of interstitial cystitis
DE10260958A1 (de) *	2002-12-20	2004-07-08	Sustech Gmbh & Co. Kg	Kompositmaterialien aus Calciumverbindungen und Glucuronsäure- und/oder Iduronsäurehaltigen Polysacchariden
US20080063677A1 (en) *	2004-03-10	2008-03-13	New Life Resources, Llc	Therapeutic, nutraceutical and cosmetic applications for eggshell membrane and processed eggshell membrane preparations
US20040180025A1 (en) *	2003-03-12	2004-09-16	New Life Resources, Llc	Therapeutic, nutraceutical and cosmetic applications for eggshell membrane and processed eggshell membrane preparations
US6946551B2 (en) *	2003-03-12	2005-09-20	New Life Resources, Llc	Preparation of hyaluronic acid from eggshell membrane
US20050176807A1 (en) *	2004-02-09	2005-08-11	Friesen Kim G.	Composition and method for use in cartilage affecting conditions
US20050176674A1 (en) *	2004-02-09	2005-08-11	Friesen Kim G.	Composition and method for use in cartilage affecting conditions
US8377904B2 (en) *	2004-02-09	2013-02-19	Hill's Pet Nutrition, Inc.	Composition and method for use in cartilage affecting conditions
US8580315B2 (en) *	2004-03-10	2013-11-12	Esm Technologies, Llc	Anti-inflammatory activity of eggshell membrane and processed eggshell membrane preparations
EP1906975A4 (de) *	2005-07-22	2010-10-06	Trf Pharma Inc	Verfahren zur behandlung von sichelzellkrankheit und folgen der sichelzellkrankheit
US9492381B1 (en)	2005-11-10	2016-11-15	Reyn Pharma, Llc	Method of administering hyaluronan formulation for preventing and ameliorating osteoarthritis
US8598144B1 (en)	2005-11-10	2013-12-03	Reyn Pharma, Llc	Method of administering hyaluronan formulation for the amelioration of osteoarthritis
US20070243218A1 (en)	2006-04-03	2007-10-18	Ellinghuysen Jerry A	Stabilized pentosan polysulfate (PPS) formulations and methods of analyzing them
JP5175481B2 (ja) *	2006-10-23	2013-04-03	エーザイフード・ケミカル株式会社	軟骨再生促進剤
BRPI0812774A2 (pt) *	2007-06-06	2014-12-02	Novus Int Inc	Suplementos alimentares para promoção de crescimento, reparo e manutenção de osso e juntas
US7947662B2 (en) *	2008-02-20	2011-05-24	Gnosis S.P.A.	Folates, compositions and uses thereof
US8163716B1 (en)	2008-06-30	2012-04-24	Smith James D	Method of administering hyaluronan formulation for the amelioration of osteophytes
US8178511B1 (en)	2008-07-02	2012-05-15	Smith James D	Method of administering hyaluronan formulation for the amelioration of osteopenia
ES2819222T3 (es) *	2009-09-23	2021-04-15	Glenpharma Ab	Composiciones y métodos para inducir o mejorar la reparación del tejido conectivo
FR2996137B1 (fr) *	2012-10-01	2017-10-27	Sp2L	Composition comprenant de l'acide hyaluronique, du manganese et de la vitamine c
EP3873415A1 (de)	2018-11-02	2021-09-08	Unilever Global Ip Limited	Bioenergetische nicotinsäureglycerinester, zusammensetzungen und verfahren zur verwendung davon
IT202100030935A1 (it)	2021-12-09	2023-06-09	Fidia Farm Spa	Compresse comprendenti condroitin solfato, glucosamina cloridrato e vitamina c per il trattamento di danni cartilaginei, tendinei, ossei

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3232836A (en)	1959-08-24	1966-02-01	Pfizer & Co C	Facilitating healing of body surface wounds by intravenous administration of n-acetyl glucosamine, glucosamine, or pharmaceutically acceptable acid salts of glucosamine
US3371012A (en)	1964-08-07	1968-02-27	Seikagaku Kogyo Co Ltd	Preservative for eye graft material
DE1792346C3 (de)	1968-08-22	1980-10-23	Rotta Research Laboratorium S.P.A., San Fruttuoso Di Monza, Mailand (Italien)	Pharmazeutisches Präparat für die Behandlung von degenerativen Gelenkerkrankungen
IT1044707B (it)	1968-10-26	1980-04-21	Rotta Research Lab	Procedimento per la preparazione di sali di glucosanina e preparati farmaceutici comprendenti detti sali di glucosamina come agenti attivi
JPS5027884A (de)	1973-07-12	1975-03-22
US4006224A (en)	1975-09-29	1977-02-01	Lescarden Ltd.	Method and agent for treating inflammatory disorders of the gastrointestinal tract
US4378224A (en)	1980-09-19	1983-03-29	Nimni Marcel E	Coating for bioprosthetic device and method of making same
US5180715A (en)	1980-11-17	1993-01-19	The Regents Of The University Of California	Irrigation of internal bladder surfaces in mammals with sodium pentosanpolysulfate
US4486416A (en)	1981-03-02	1984-12-04	Soll David B	Protection of human and animal cells subject to exposure to trauma
IT1137892B (it)	1981-08-24	1986-09-10	Bioresearch Srl	Sali stabili della s-adenosilmetionina,processo per la loro preparazione e composizioni terapeutiche che li comprendono come principio attivo
IT1137640B (it)	1981-08-24	1986-09-10	Bioresearch Srl	Sali stabili della s-adenosilmetionina,processo per la loro preparazione e composizioni terapeutiche che li comprendono come principio attivo
US4473551A (en)	1982-08-23	1984-09-25	Faxon Pharmaceuticals, Inc.	Anti-inflammatory composition
FR2543145B1 (fr)	1983-03-24	1986-10-17	Sanofi Sa	Nouveaux sulfates de xylanes, leur procede de preparation et leur activite anti-thrombotique et hypolipemiante
IT1173990B (it)	1984-05-16	1987-06-24	Bioresearch Spa	Sali stabili della solfo-adenosil-l-metionina (same) particolarmente adatti per uso parenterale
IT1173992B (it)	1984-05-16	1987-06-24	Bioresearch Spa	Sali stabili della solfo-adenosil-l-metionina (same) particolarmente idonei per uso farmaceutico orale
US4711780A (en)	1984-06-11	1987-12-08	Fahim Mostafa S	Composition and process for promoting epithelial regeneration
DE3422407A1 (de)	1984-06-16	1986-03-06	B. Braun Melsungen Ag, 3508 Melsungen	Verwendung von heparinderivaten zur selektiven extrakorporalen praezipitation von low-density-lipoproteinen aus vollserum oder plasma
DE3432661A1 (de)	1984-09-05	1986-03-06	Albert Prof. Dr. 6907 Nußloch Landsberger	Carcinom-therapeutikum
US4647453A (en)	1984-10-18	1987-03-03	Peritain, Ltd.	Treatment for tissue degenerative inflammatory disease
FR2572731B1 (fr)	1984-11-07	1987-03-06	Sanofi Sa	Nouveaux sulfates de xylanes de bas poids moleculaires, leur procede de preparation et leur activite antithrombotique et hypolipemiante par voie orale
SE8501723L (sv)	1985-04-09	1986-10-10	Pharmacia Ab	Preparation att anvendas vid behandling av ledinflammation
US4707354A (en)	1985-06-17	1987-11-17	Alpen Tau, Inc.	Mature skin treatment and protectant compositions and methods of using same
US4772591A (en)	1985-09-25	1988-09-20	Peritain, Ltd.	Method for accelerated wound healing
DE3602670A1 (de)	1986-01-29	1987-07-30	Speck Ulrich	Verwendung von n-acetylglucosamin zur therapie degenerativer gelenkprozesse und verwandter erkrankungen
US4966890A (en)	1986-04-04	1990-10-30	Angiogenics, Ltd.	Method and composition for arresting angiogenesis and capillary, cell or membrane leakage
US4820693A (en)	1986-05-22	1989-04-11	Angiogenics, Ltd.	Method and composition for arresting angiogenesis and capillary, cell or membrane leakage
US4983580A (en)	1986-04-04	1991-01-08	Allergan, Inc.	Methods and materials for use in corneal wound healing
US5091171B2 (en)	1986-12-23	1997-07-15	Tristrata Inc	Amphoteric compositions and polymeric forms of alpha hydroxyacids and their therapeutic use
US5385938B1 (en)	1986-12-23	1997-07-15	Tristrata Inc	Method of using glycolic acid for treating wrinkles
US5668116A (en)	1987-03-19	1997-09-16	Anthropharm Pty. Limited	Anti-inflammatory compounds and compositions
EP0356435B1 (de) *	1987-03-19	1995-10-18	Arthropharm Pty. Limited	Antientzündungsmittel und zusammensetzungen
US5263984A (en)	1987-07-20	1993-11-23	Regen Biologics, Inc.	Prosthetic ligaments
FR2609397B1 (fr)	1988-02-23	1991-12-13	Serobiologiques Lab Sa	Utilisation d'une substance ou composition de nature glucidique comme principe actif d'une composition dermatologique et/ou cosmetologique et/ou pharmaceutique et/ou stimulante cellulaire, et composition contenant une telle substance ou composition de nature glucidique
US5510418A (en)	1988-11-21	1996-04-23	Collagen Corporation	Glycosaminoglycan-synthetic polymer conjugates
GB8900812D0 (en)	1989-01-14	1989-03-08	Univ Manchester	Pharmaceutical method and compositions
FR2649982B1 (fr)	1989-07-20	1991-09-27	Inst Nat Sante Rech Med	Membrane biologique artificielle
DE3942081A1 (de)	1989-12-20	1991-06-27	Behringwerke Ag	Mittel zur verbesserung der wiederfindung von annexinen
US5141928B1 (en)	1989-12-20	1995-11-14	Brujo Inc	Ophthalmic medication
US5514667A (en)	1990-11-05	1996-05-07	Arthropharm Pty. Limited	Method for topical treatment of herpes infections
AU1052492A (en)	1991-01-31	1992-08-06	Farmitalia Carlo Erba S.R.L.	Synergistic composition comprising a fibroblast growth factor and a sulfated polylsaccharide, for use as antiviral agent
US5272135A (en)	1991-03-01	1993-12-21	Chiron Ophthalmics, Inc.	Method for the stabilization of methionine-containing polypeptides
IT1260137B (it)	1992-04-17	1996-03-28	Alfa Wassermann Spa	Glicosaminoglicani semisintetici a struttura eparinica od eparanica modificati nella posizione 2 dell'acido alfa-l-iduronico-2-0-solfato
JPH06192109A (ja)	1992-09-04	1994-07-12	Fuji Kagaku Kogyo Kk	抗腫瘍効果増強剤
IT1264101B1 (it)	1993-03-29	1996-09-10	Alfa Wassermann Spa	Processo per la sintesi di glicosaminoglicani semisintetici a struttura eparinica od eparanica modificati nella posizione 2
IT1264102B1 (it)	1993-03-29	1996-09-10	Alfa Wassermann Spa	Processo per la sintesi di glicosaminoglicani semisintetici contenenti acido alfa-l-galatturonico sostituito con radicali
US5364845C1 (en) *	1993-03-31	2002-09-10	Nutramax Lab Inc	Glusosamine chondroitin and manganese composition for the protection and repair of connective tissue
US5691325A (en)	1994-01-14	1997-11-25	Sandyk; Reuven	Method for ameliorating age-related disease conditions
US5597575A (en)	1994-06-06	1997-01-28	Breitbarth; Richard	Composition for stimulating and inducing hair growth
US5639787A (en)	1995-02-28	1997-06-17	The Center For The Improvement Of Human Functioning Int'l, Inc.	Therapeutic method for the treatment of cancer
WO1996033703A2 (en) *	1995-04-25	1996-10-31	Oridigm Corporation	S-adenosyl methionine regulation of metabolic pathways and its use in diagnosis and therapy
CA2224088A1 (en)	1995-06-07	1996-12-19	Monsanto Company	Process for preparing substituted polyazamacrocycles
US5643892A (en)	1995-06-07	1997-07-01	Baker Norton Pharmaceuticals, Inc.	Method of treating chronic progressive vascular diseases
GB2317109B (en) *	1996-08-28	2000-06-21	Farmsense	A therapeutic composition for the treatment and repair of connective tissue in mammals

1997
- 1997-04-28 US US08/845,852 patent/US6255295B1/en not_active Expired - Lifetime
1998
- 1998-04-17 PT PT98915591T patent/PT979090E/pt unknown
- 1998-04-17 NZ NZ500025A patent/NZ500025A/en not_active IP Right Cessation
- 1998-04-17 CA CA002539696A patent/CA2539696A1/en active Pending
- 1998-04-17 AT AT07075664T patent/ATE489099T1/de not_active IP Right Cessation
- 1998-04-17 AU AU69733/98A patent/AU747595B2/en not_active Expired
- 1998-04-17 ES ES98915591T patent/ES2324565T3/es not_active Expired - Lifetime
- 1998-04-17 ES ES07075664T patent/ES2357255T3/es not_active Expired - Lifetime
- 1998-04-17 DE DE69842021T patent/DE69842021D1/de not_active Expired - Lifetime
- 1998-04-17 CA CA002286552A patent/CA2286552C/en not_active Expired - Fee Related
- 1998-04-17 DE DE69840668T patent/DE69840668D1/de not_active Expired - Lifetime
- 1998-04-17 EP EP07075664A patent/EP1849471B1/de not_active Expired - Lifetime
- 1998-04-17 WO PCT/US1998/007561 patent/WO1998048816A1/en not_active Ceased
- 1998-04-17 CA CA002539919A patent/CA2539919A1/en not_active Abandoned
- 1998-04-17 AT AT98915591T patent/ATE425757T1/de active
- 1998-04-17 DK DK98915591T patent/DK0979090T3/da active
- 1998-04-17 EP EP98915591A patent/EP0979090B1/de not_active Expired - Lifetime
2009
- 2009-05-13 CY CY20091100511T patent/CY1109064T1/el unknown

Also Published As

Publication number	Publication date
DE69840668D1 (de)	2009-04-30
NZ500025A (en)	2002-03-01
PT979090E (pt)	2009-05-04
ATE489099T1 (de)	2010-12-15
US6255295B1 (en)	2001-07-03
ES2324565T3 (es)	2009-08-10
CA2539696A1 (en)	1998-11-05
CA2286552A1 (en)	1998-11-05
DE69842021D1 (de)	2011-01-05
CA2539919A1 (en)	1998-11-05
EP0979090A4 (de)	2000-10-18
EP1849471B1 (de)	2010-11-24
HK1114774A1 (en)	2008-11-14
EP1849471A1 (de)	2007-10-31
CY1109064T1 (el)	2014-07-02
AU6973398A (en)	1998-11-24
WO1998048816A1 (en)	1998-11-05
ATE425757T1 (de)	2009-04-15
ES2357255T3 (es)	2011-04-20
EP0979090B1 (de)	2009-03-18
EP0979090A1 (de)	2000-02-16
CA2286552C (en)	2007-10-30
AU747595B2 (en)	2002-05-16

Publication	Publication Date	Title
ATE489099T1 (de)	2010-12-15	Aminozucker, chondroitin und s-adenosylmethionin enthaltende zusammensetzungen
CA2159591A1 (en)	1994-10-13	Aminosugar and Glycosaminoglycan Composition for the Treatment and Repair of Connective Tissue
ES2374157T3 (es)	2012-02-14	Tratamiento para la sinovitis traumática y el cartílago articular dañado.
US6583123B2 (en)	2003-06-24	Aminosugar, glycosaminoglycan, and S-adenosylmethionine composition for the treatment and repair of connective tissue
de los Reyes et al.	2000	Glucosamine and chondroitin sulfates in the treatment of osteoarthritis: a survey
BR0009651A (pt)	2002-01-08	Composto, processo para a preparação de um composto, composição farmacêutica, uso de um composto, e, método para tratar artrite reumatóide e uma doença obstrutiva das vias aéreas
PT91420A (pt)	1990-03-08	Processo para a preparacao de uma composicao farmaceutica para o tratamento da diabetes mellitus
BR9809492A (pt)	2000-06-20	Composição farmacêutica aquosa injetável, e, processo para a preparação da mesma
JP2002516866A5 (de)	2006-01-05
WO1999062524A1 (en)	1999-12-09	Aminosugar, glycosaminoglycan, and s-adenosylmethionine composition for the treatment and repair of connective tissue
DE69333005D1 (de)	2003-07-03	Zusammensetzungen von hyaluronat mit bimodalem molekulargewicht und verfahren zu deren verwendung
DE60035227D1 (de)	2007-07-26	Oral zu verabreichende zubereitungen von nahrungsmittelzusätzen zur heilung von gelenkknorpeln
Mejersjö et al.	1987	Effect of corticosteroid and sodium hyaluronate on induced joint lesions in the guinea-pig knee
Cylwik et al.	2004	The influence of doxycycline on articular cartilage in experimental osteoarthrosis induced by iodoacetate
CA2314817A1 (en)	2001-12-06	Synergistic agents for enhancing tissue repair
BR9808216A (pt)	2000-05-16	Composição cosmética ou farmacêutica contendo pelo menos um retinóide
Canapp	2003	Medical management of osteoarthrosis.
TH96545A (th)	2009-07-09	สารหยุ่นหนืดชนิดต่างๆ สำหรับใช้ระหว่างการผ่าตัด
Koda	2012	Gerlie C. de los Reyes
HK1114774B (en)	2011-04-21	Compositions comprising an aminosugar, chondroitin, and s-adenosylmethionine